Introduction
GPC Biotech (GPC), founded in 1997, has a business model relied on two pillars, as a service provider for preclinical research and as a product company with its own development pipeline. Later, the company changed its focus by developing a platform of base technologies, LeadCode, through collaborations with pharmaceutical partners and through the support of its own drug development projects.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
GPC is a biopharmaceutical company focused on discovery, development and commercialization of new anticancer drugs, Cell Cycle Inhibitors and antibodies against MHC class II-positive tumor cells. It's most advanced product candidate satraplatin is currently in SPARC Phase III trial, for the treatment of hormone-refractory prostate cancer. The company's second lead product candidate, 1D09C3, is in Phase I clinical trials and is a monoclonal antibody indicated for the treatment of relapsed/refractory B-cell lymphomas, such as Hodgkin's and non-Hodgkin's lymphomas and chronic lymphocytic leukemia. The company's total revenues increased at a CAGR of 1.3% during 2002-2006, from $27.6 million to $29.1 million. This represents an absolute total growth of +$1.5 million during the historical period. The company's biggest contributor to revenue growth during 2002-2006 was license, collaboration and other revenues.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization.
Report Highlights
[Studien Infos ausblenden]
